Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos)

[1]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[2]  R. Goeree,et al.  The burden of illness of osteoporosis in Canada , 2012, Osteoporosis International.

[3]  L. Lix,et al.  Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts , 2011, Osteoporosis International.

[4]  J. Kanis,et al.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.

[5]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[6]  D. Beaton,et al.  Osteoporosis quality indicators using healthcare utilization data , 2010, Osteoporosis International.

[7]  S. Maggi,et al.  Effect of Inhaled Glucocorticoids and β2 Agonists on Vertebral Fracture Risk in COPD Patients: The EOLO Study , 2010, Calcified Tissue International.

[8]  Lehana Thabane,et al.  Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study , 2009, Canadian Medical Association Journal.

[9]  P. Vestergaard,et al.  Fracture Risk Associated with Different Types of Oral Corticosteroids and Effect of Termination of Corticosteroids on the Risk of Fractures , 2008, Calcified Tissue International.

[10]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[11]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[12]  Jacques P. Brown,et al.  Recommendations for bone mineral density reporting in Canada. , 2005, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[13]  P. Delmas,et al.  Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: A biochemical and histomorphometric study , 1993, Osteoporosis International.

[14]  K. Nakao,et al.  High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass , 2005, Osteoporosis International.

[15]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  A. LaCroix,et al.  Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials , 2004, Menopause.

[17]  P. Ross,et al.  Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study , 1995, Calcified Tissue International.

[18]  Stanley B. Cohen,et al.  Oral glucocorticoid use is associated with an increased risk of fracture , 2004, Osteoporosis International.

[19]  C. Cooper,et al.  The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis , 2002, Osteoporosis International.

[20]  C. Cooper,et al.  Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study , 2002, Osteoporosis International.

[21]  S. A. Jackson,et al.  The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada , 2001, Osteoporosis International.

[22]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[24]  S. A. Jackson,et al.  Vertebral Fracture Definition from Population-Based Data: Preliminary Results from the Canadian Multicenter Osteoporosis Study (CaMos) , 2000, Osteoporosis International.

[25]  Jacques P. Brown,et al.  Research Notes: The Canadian Multicentre Osteoporosis Study (CaMos): Background, Rationale, Methods , 1999, Canadian Journal on Aging / La Revue canadienne du vieillissement.

[26]  L. Marinis,et al.  Corticotropin-releasing hormone inhibition of gonadotropin secretion during the menstrual cycle. , 1989, Metabolism: clinical and experimental.